Shandong Weigao Group Medical Polymer Co Ltd Unsponsored American Depository Receipt REPSTG SHS H (SHWGY) –
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$8.70 at Goldman Sachs
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$8.45 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$10 at Goldman Sachs
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$10.30 at Morgan Stanley
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$12.70 at Goldman Sachs
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$14.30 at UBS
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$13 at Citi
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$17 at Jefferies
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$9.91 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$13.90 at Goldman Sachs
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$13.26 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$14.79 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Raised to HK$15.90 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Raised to HK$13.33 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$13 at Goldman Sachs
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$3.08 at Goldman Sachs
-
Nomura/Instinet Reiterates Buy Rating on Shandong Weigao Group Medical (1066:HK) (SHWGY)
-
Morgan Stanley Reiterates Equalweight Rating on Shandong Weigao Group Medical (1066:HK) (SHWGY)
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Raised to HK$12.64 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Raised to HK$12.55 at Nomura/Instinet
-
Morgan Stanley Reiterates Equalweight Rating on Shandong Weigao Group Medical (1066:HK) (SHWGY)
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$12.26 at Nomura/Instinet
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$13 at Credit Suisse
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$13.56 at Nomura/Instinet
-
Goldman Sachs Reiterates Neutral Rating on Shandong Weigao Group Medical (1066:HK) (SHWGY)
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$17.30 at Morgan Stanley
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$16 at Credit Suisse
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Lowered to HK$16.20 at Goldman Sachs
-
Goldman Sachs Downgrades Shandong Weigao Group Medical (1066:HK) (SHWGY) to Neutral
-
Macquarie Upgrades Shandong Weigao Group Medical (1066:HK) (SHWGY) to Outperform
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Raised to HK$15.48 at Goldman Sachs
-
Citi Downgrades Shandong Weigao Group Medical (1066:HK) (SHWGY) to Neutral
-
UOB Kay Hian Reiterates Hold Rating on Shandong Weigao Group Medical (SHWGY)
-
ACell Enters Exclusive Chinese Product Supply and Distribution Agreement for Cytal and MicroMatrix Wound Management Products
-
Shandong Weigao Group Medical (1066:HK) (SHWGY) PT Raised to HK$6.90 at Credit Suisse
-
Misonix, Inc. Enters into Exclusive Chinese Distribution Agreement for BoneScalpel
-
Amedica (AMDA) Enters Exclusive Silicon Nitride Distribution Agreement in China
-
Amedica Signs Exclusive Chinese Silicon Nitride Distribution Agreement
Back to SHWGY Stock Lookup